We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama... Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. The company has additional operations facilities in Huntsville, Alabama, and Hyderabad, India. Show more
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference PR Newswire SAN FRANCISCO, March 22, 2024 SAN FRANCISCO, March 22, 2024...
FYfalse0000906709P3Y130000906709us-gaap:FacilityClosingMember2023-12-310000906709nktr:TwoThousandTwentyTwoAndTwoThousandTwentyThreeRestructuringPlansMember2023-01-012023-03-310000906709nktr:TwoThou...
Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata PR Newswire SAN FRANCISCO, March 5, 2024...
false 0000906709 0000906709 2024-03-04 2024-03-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED...
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results PR Newswire SAN FRANCISCO, March 4, 2024 SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:...
NASDAQ false 0000906709 0000906709 2024-03-04 2024-03-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT...
Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX PR Newswire SAN FRANCISCO, March 4, 2024 SAN FRANCISCO, March 4, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:...
Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference PR Newswire SAN FRANCISCO, Feb. 27, 2024 SAN FRANCISCO, Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq:...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.007 | 0.766703176342 | 0.913 | 0.94 | 0.84 | 1193499 | 0.89491042 | CS |
4 | 0.18 | 24.3243243243 | 0.74 | 1.08 | 0.7015 | 2569406 | 0.88628212 | CS |
12 | 0.3599 | 64.2563827888 | 0.5601 | 1.08 | 0.48 | 1633210 | 0.77418102 | CS |
26 | 0.3238 | 54.3106340154 | 0.5962 | 1.08 | 0.4126 | 1588054 | 0.633482 | CS |
52 | 0.146 | 18.8630490956 | 0.774 | 1.12 | 0.4126 | 3697720 | 0.75767537 | CS |
156 | -18.93 | -95.3652392947 | 19.85 | 20.9 | 0.4126 | 2676166 | 4.0958788 | CS |
260 | -30.92 | -97.1105527638 | 31.84 | 37 | 0.4126 | 2303562 | 9.54716175 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions